



Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference

SAN DIEGO, November 20, 2019 —Pfenex Inc. (NYSE American: PFINX) is a development and licensing biotechnology company focused on leveraging its *Pf*enex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented *Pf*enex Expression Technology platform, the Company has developed the FDA-approved PF708 product indicated for the treatment of osteoporosis in certain patients at high risk of fracture and created an advanced pipeline of therapeutic equivalents, biologics and vaccines. The Company announced today that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4th, taking place at the Lotte New York Palace in New York.

Piper Jaffray 31st Annual Healthcare Conference

Date: Wednesday, December 4, 2019

Time: 10:00 a.m. Eastern Time

Interested parties can access the live audio webcast and archive from the Investors Section of Pfenex's website at www.pfenex.com.

About Pfenex Inc.

Pfenex is a development and licensing biotechnology company focused on leveraging its *Pf*enex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented *Pf*enex Expression Technology platform, Pfenex has created an advanced pipeline of potential therapeutic equivalents, and vaccines. Pfenex's lead product candidate is PF708, a therapeutic equivalent candidate to Forteo® (teriparatide injection). PF708 has been approved in the U.S. for the treatment of osteoporosis in certain patients at high risk of fracture, and marketing authorization applications are pending in other jurisdictions. In addition, Pfenex is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology. Pfenex also uses its *Pf*enex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccines.

Pfenex investors and others should note that Pfenex announces material information to the public about Pfenex through a variety of means, including its website (<http://www.pfenex.com/>), its investor relations website (<http://pfenex.investorroom.com/>), press releases, SEC filings, public conference calls, corporate Twitter account (<https://twitter.com/pfenex>), Facebook page (<https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/>), and LinkedIn page (<https://www.linkedin.com/company/pfenex-inc>) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with its disclosure obligations under Regulation FD. Pfenex encourages its investors and others to monitor and review the information Pfenex makes public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Investor Contact:

Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
Office: 617-430-7578

hans@lifesciadvisors.com